Study of Rivaroxaban for CeREbral Venous Thrombosis
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
SECRET examines the safety of rivaroxaban versus standard-of-care for treatment of
symptomatic cerebral venous thrombosis, initiated within 14 days of diagnosis.